Our story

The natural evolution of insulin delivery

For decades, insulin pen technology has transformed diabetes care—but only for those who can afford it. When GO-Pen's co-founders looked at this problem, they saw an engineering challenge: adapt proven pen technology to work with affordable insulin vials. That’s how GO-Pen was born. To us, this isn't revolutionary technology. It's the logical next step in insulin pen design.

Why this hasn't been solved before

The obstacle hasn't been technical - it's been focus. Medical innovation gravitates toward high-tech solutions and premium segments. This has left millions underserved. GO-Pen fills this gap, proving that accessible innovation can be both clinically effective and commercially viable.

Driven by purpose

GO-Pen is founded on a purpose of creating equal access to quality diabetes.

Our vision is that all people with diabetes who need insulin have access to an affordable insulin pen.

Our mission is to develop a low-cost, high-quality and environmentally sound insulin pen that democratizes access to modern diabetes technology, eliminating the 20+ million person gap between those using syringes and those with access to pen systems.

In 2025, we're completing commercial launch preparations in key markets, establishing distribution partnerships across multiple continents, and beginning to reach the first patients through commercial channels. Our ultimate goal remains unchanged: ensuring that advances in diabetes care reach everyone who needs them, everywhere in the world.

Responsibility

We aim to balance environmental and social impact by creating equal access to quality diabetes care while minimizing environmental impact through evidence-based design and continuous optimization.

This is reflected in the decisions we make about design, production and distribution of our product. Our approach to sustainability stands on the three solid ESG pillars:

  • Environmental stewardship

  • Social impact

  • Responsible governance

Environmental stewardship

73% lower carbon footprint

GO-Pen generates 8,97 kg CO2-eq compared to 33.10 kg CO2-eq for single-use syringes per functional unit.*

Before moving into large-scale production, we proactively partnered with Before moving into large-scale production, we proactively partnered with DTU, the Danish Technical University, to conduct a comprehensive Life Cycle Assessment following ISO 14040/44 standards. This upfront analysis allows us to integrate environmental considerations into our planning and decision-making from the outset.

The LCA compared GO-Pen against 1.0 mL single-use syringes across the complete product lifecycle, assessing 1,460 insulin injections - equivalent to one year of treatment with four daily injections - delivered in Denmark. The results demonstrate that GO-Pen has a 73% lower carbon footprint compared to syringes.

By identifying environmental hotspots early in our development process, we can scale production while maintaining our commitment to both patient care and planetary stewardship.

With one pen lasting up to three years and a 73% lower carbon footprint compared to syringes, we're proving that quality healthcare and environmental stewardship can work hand in hand.

Significant Plastic Reduction One 3-year GO-Pen eliminates the need for thousands of disposable syringes. Each GO-Pen reservoir contains the same amount of insulin as 21 individual syringes, dramatically reducing plastic waste.

*Important context: The LCA assumes single-use practice for syringes as per Danish healthcare standards. In many low- and middle-income countries, economic constraints lead to syringe reuse, which may affect comparative environmental impact, though GO-Pen's fundamental sustainability benefits remain significant.

Social impact

GO-Pen is not just building a product; we're building a movement toward health equity in diabetes care. By making modern insulin delivery technology accessible to the 20+ million people worldwide still dependent on syringes, GO-Pen is addressing a fundamental health inequality that has persisted for decades.

Responsible governance

Our team's combined experience in diabetes care, regulatory excellence, and sustainable business practices guides our decision-making. We consider long-term impact on people, healthcare systems, and environmental outcomes in everything we do.

GO-Pen aligns with the UN Sustainable Development Goals with a particular focus on:

  • SDG 3: Good Health and Well-being

  • SDG 8: Decent Work and Economic Growth

  • SDG 9: Industry, Innovation and Infrastructure

  • SDG 10: Reduced Inequalities

  • SDG 12: Responsible Consumption and Production